DOJ Seeks Pause in Missouri Mifepristone Suit Amid FDA Review Strategy

The Department of Justice’s recent filing in a Missouri federal court represents a significant tactical shift in the high-stakes legal battle over the pharmaceutical regulation of mifepristone. By requesting a stay or dismissal of the lawsuit led by Missouri, Kansas, and Idaho, the DOJ is attempting to pivot the conflict away from the judiciary and back toward the administrative authority of the FDA. This strategy, which mirrors a similar request made in Louisiana earlier this year, indicates that the administration is seeking to manage the regulatory future of the abortion pill through internal agency reviews rather than allowing state-led litigation to dictate immediate, nationwide changes to drug access.

The Missouri lawsuit specifically targets the FDA’s long-standing safety data and its subsequent decisions to expand access to mifepristone. The plaintiffs, led by Missouri Attorney General Catherine Hanaway, are demanding that the FDA roll back its approval window from ten weeks of gestation to seven and reinstate a ban on telehealth prescriptions. The core of the legal challenge rests on the claim that mail-order distribution of the drug is inherently dangerous—a position that directly conflicts with the FDA’s 2021 decision to permanently allow remote prescribing. For the pharmaceutical and biotech sectors, this challenge represents a direct assault on the telehealth and mail-order pharmacy models that have become integral to modern drug delivery.

“

The plaintiffs, led by Missouri Attorney General Catherine Hanaway, are demanding that the FDA roll back its approval window from ten weeks of gestation to seven and reinstate a ban on telehealth prescriptions.

In its filing, the DOJ argued that the FDA is currently undertaking its own review based on the evidence before the agency, asserting that overlapping lawsuits would create regulatory confusion. This "FDA review" defense serves as a dual-purpose tool: it provides a legal basis for delaying court rulings that could be politically volatile ahead of midterm elections, and it signals a potential willingness by the agency to voluntarily revise its own guidelines. However, the lack of transparency regarding the scope or timeline of this internal review has left both advocates and industry stakeholders in a state of uncertainty. If the FDA chooses to self-impose restrictions to settle these lawsuits, it could establish a precedent where political litigation successfully bypasses the traditional scientific review process.